文献速递瓣膜病与结构性心脏病血脂与心血管预防

二肽基肽酶-4抑制与钙化性主动脉瓣狭窄进展

Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis.
PubMed 文献 · Heart · 2020-09-11

本研究评估DPP-4抑制剂及其心脏组织分布和抗钙化能力与主动脉瓣狭窄进展风险的关联。在212例糖尿病合并轻中度AS患者中,具有 favourable 药代/药效特性的DPP-4抑制剂与较低的AS进展风险相关。

要点

  • DPP-4抑制剂整体使用与未使用者AS进展无显著差异。
  • favourable DPP-4抑制剂组Vmax增加显著低于 unfavourable 或未使用组。
  • favourable组严重AS进展风险显著低于其他组(HR 0.116)。

核心结论

  • 具有 favourable 药代动力学和药效学特性的DPP-4抑制剂与较低的AS进展风险相关。

研究设计与样本

  • 回顾性队列研究,纳入212例糖尿病合并轻中度AS患者(72±8岁,111例男性),中位随访3.7年。

主要发现

  • 随访期间Vmax从2.9±0.3增至3.5±0.7 m/s,DPP-4使用者整体与未使用者变化无差异(p=0.143)。
  • favourable组Vmax增加显著低于 unfavourable 或未使用组(p=0.018)。
  • 严重AS进展在 favourable组为7.1%,低于 unfavourable组29.0%(p=0.03)和未使用组29.6%(p=0.01)。
  • 调整年龄、基线肾功能和AS严重程度后, favourable组严重AS进展风险显著降低(HR 0.116,95%CI 0.024-0.551,p=0.007)。

临床怎么用

  • 在糖尿病合并轻中度AS患者中,选择具有 favourable 药代/药效特性的DPP-4抑制剂可能有助于延缓AS进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether the use of dipeptidyl peptidase-4 (DPP-4) inhibitors and their cardiac tissue distribution profile and anticalcification abilities are associated with risk of aortic stenosis (AS) progression. METHODS: Out of the five different classes of DPP-4 inhibitors, two had relatively favourable heart to plasma concentration ratios and anticalcification ability in murine and in vitro experiments and were thus categorised as 'favourable'. We reviewed the medical records of 212 patients (72±8 years, 111 men) with diabetes and mild-to-moderate AS who underwent echocardiographic follow-up and classified them into those who received favourable DPP-4 inhibitors (n=28, 13%), unfavourable DPP-4 inhibitors (n=69, 33%) and those who did not receive DPP-4 inhibitors (n=115, 54%). RESULTS: Maximal transaortic velocity (Vmax) increased from 2.9±0.3 to 3.5±0.7 m/s during follow-up (median, 3.7 years), and the changes were not different between DPP-4 users as a whole and non-users (p=0.143). However, the favourable group showed significantly lower Vmax increase than the unfavourable or non-user group (p=0.018). Severe AS progression was less frequent in the favourable group (7.1%) than in the unfavourable (29.0%; p=0.03) or the non-user (29.6%; p=0.01) group. In Cox regression analysis after adjusting for age, baseline renal function and AS severity, the favourable group showed a significantly lower risk of severe AS progression (HR 0.116, 95% CI 0.024 to 0.551, p=0.007). CONCLUSIONS: DPP-4 inhibitors with favourable pharmacokinetic and pharmacodynamic properties were associated with lower risk of AS progression. These results should be considered in the preparation of randomised clinical trials on the repositioning of DPP-4 inhibitors.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Lee S, Lee SA, Choi B, et al. Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis. Heart. 2020. PMID: 32917732. doi:10.1136/heartjnl-2020-317024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。